Sarepta prices Duchenne gene therapy at $3.2M

The first gene therapy for Duchenne muscular dystrophy will cost $3.2 million, its developer, biotechnology company Sarepta Therapeutics, said on Thursday.

The price makes the drug, named Elevidys and approved by the Food and Drug Administration earlier Thursday, one of the most expensive medicines in the U.S. on a single-use basis. It’s surpassed only by Hemgenix, a hemophilia B gene therapy cleared last year that costs $3.5 million per patient.